High Throughput Mitochondrial Nephrotoxicant Assay

高通量线粒体肾毒测定

基本信息

  • 批准号:
    8334035
  • 负责人:
  • 金额:
    $ 80.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-30 至 2015-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The kidney is a target of toxicity from drugs, and industrial and environmental chemicals because of its high blood flow, numerous transporters, and reliance on aerobic metabolism. Not surprisingly, mitochondria are a common intracellular target of chemicals in multiple organs, leading to decreased aerobic metabolism and ATP, and cell death. Current in vitro models of nephrotoxicity and mitochondrial damage are inadequate for many of the same reasons: cultured cells are very glycolytic with minimal aerobic metabolism, and there are no moderate or high-throughput real-time metabolomic assays. Consequently, new cellular models and metabolomic methodologies are needed to evaluate nephrotoxicity and mitochondrial damage. We have developed primary cultures of renal proximal tubular cells (RPTC) that exhibit in vivo levels of aerobic metabolism, are not glycolytic and retain higher levels of differentiated functions. We previously developed primary cultures of renal proximal tubular cells (RPTC) that exhibit in vivo levels of aerobic metabolism, are not glycolytic, and retain higher levels of differentiated functions. The goal of the Phase I proposal was to merge our novel and relevant RPTC model and the Seahorse technology to develop a high-throughput assay to accurately measure nephrotoxicity. In addition to completing the objectives described in the Phase I aims, we also developed a cheminformatic strategy in which chemical similarity is used to cluster molecules that are then modeled to define a potential "toxicophore" of similar physicochemical features in 3-dimesional space. These chemical entities/toxicophores that damage mitochondria are predicted to be nephrotoxicants. Our goals for Phase are to validate our integrated metabolic and imaging assay using the TOXNET & Toxcast land to use cheminformatic analyses to develop a toxicophore database. This RPTC/Seahorse platform will identify nephrotoxicants and mitochondrial toxicants and provide public companies and regulatory agencies with mechanism and chemical-based criteria for assessing and predicting nephrotoxicity and mitochondrial toxicity of new drugs, consumer products, and environmental agents, and shorten the overall time to identify potential problem chemicals. The commercialization plan is to offer these screening and cheminformatic services to pharmaceutical & federal agencies.
描述(由申请人提供):肾脏是药物、工业和环境化学品毒性的靶点,因为其血流量高、转运蛋白众多且依赖于有氧代谢。毫不奇怪,线粒体是多个器官中化学物质的常见细胞内靶点,导致有氧代谢和ATP减少以及细胞死亡。由于许多相同的原因,目前的肾毒性和线粒体损伤的体外模型是不够的:培养的细胞非常糖酵解,有氧代谢最少,没有中等或高通量的实时代谢组学测定。因此,需要新的细胞模型和代谢组学方法来评价肾毒性和线粒体损伤。我们已经开发了肾近端小管细胞(RPTC)的原代培养物,其表现出体内有氧代谢水平,不糖酵解,并保留较高水平的分化功能。我们以前开发的原代培养肾近端小管细胞(RPTC),表现出体内有氧代谢水平,不糖酵解,并保留较高水平的分化功能。第一阶段提案的目标是将我们的新型相关RPTC模型与Seahorse技术相结合,以开发一种高通量检测方法,从而准确测量肾毒性。除了完成第一阶段目标中描述的目标外,我们还开发了一种化学信息学策略,其中化学相似性用于聚类分子,然后建模以定义三维空间中相似物理化学特征的潜在“毒团”。预计这些损害线粒体的化学实体/毒粒是肾毒物。我们的阶段目标是使用TOXNET和Toxcast验证我们的综合代谢和成像分析,并使用化学信息学分析开发毒基数据库。该RPTC/Seahorse平台将识别肾毒性物质和线粒体毒性物质,并为上市公司和监管机构提供基于机制和化学的标准,用于评估和预测新药、消费品和环境因子的肾毒性和线粒体毒性,并缩短识别潜在问题化学品的总时间。商业化计划是为制药和联邦机构提供这些筛选和化学信息服务。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Systematic study of mitochondrial toxicity of environmental chemicals using quantitative high throughput screening.
  • DOI:
    10.1021/tx4001754
  • 发表时间:
    2013-09-16
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Attene-Ramos MS;Huang R;Sakamuru S;Witt KL;Beeson GC;Shou L;Schnellmann RG;Beeson CC;Tice RR;Austin CP;Xia M
  • 通讯作者:
    Xia M
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Craig Cano Beeson其他文献

Craig Cano Beeson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Craig Cano Beeson', 18)}}的其他基金

Development of a lasmiditan analogue for treatment of acute kidney injury
开发用于治疗急性肾损伤的 lasmiditan 类似物
  • 批准号:
    8781967
  • 财政年份:
    2014
  • 资助金额:
    $ 80.07万
  • 项目类别:
High Throughput Extracellular Flux Analyzer
高通量细胞外通量分析仪
  • 批准号:
    8052392
  • 财政年份:
    2011
  • 资助金额:
    $ 80.07万
  • 项目类别:
Inducers of Mitochondrial Biogenesis
线粒体生物发生诱导剂
  • 批准号:
    8200080
  • 财政年份:
    2011
  • 资助金额:
    $ 80.07万
  • 项目类别:
Bioenergetics Core
生物能核心
  • 批准号:
    10005395
  • 财政年份:
    2011
  • 资助金额:
    $ 80.07万
  • 项目类别:
High Throughput Mitochondrial Nephrotoxicant Assay
高通量线粒体肾毒测定
  • 批准号:
    8253245
  • 财政年份:
    2010
  • 资助金额:
    $ 80.07万
  • 项目类别:
High Throughput Mitochondrial Nephrotoxicant Assay
高通量线粒体肾毒测定
  • 批准号:
    8001529
  • 财政年份:
    2010
  • 资助金额:
    $ 80.07万
  • 项目类别:
Optimization of dipeptide-linked benzimidazole topoisomerase 1 poisons
二肽连接苯并咪唑拓扑异构酶1毒物的优化
  • 批准号:
    7665607
  • 财政年份:
    2009
  • 资助金额:
    $ 80.07万
  • 项目类别:
BINDING INTERACTIONS WITHIN PEPTIDE-MHC COMPLEXES
肽-MHC 复合物内的结合相互作用
  • 批准号:
    6386567
  • 财政年份:
    2000
  • 资助金额:
    $ 80.07万
  • 项目类别:
BINDING INTERACTIONS WITHIN PEPTIDE-MHC COMPLEXES
肽-MHC 复合物内的结合相互作用
  • 批准号:
    6127991
  • 财政年份:
    2000
  • 资助金额:
    $ 80.07万
  • 项目类别:
BINDING INTERACTIONS WITHIN PEPTIDE-MHC COMPLEXES
肽-MHC 复合物内的结合相互作用
  • 批准号:
    6690625
  • 财政年份:
    2000
  • 资助金额:
    $ 80.07万
  • 项目类别:

相似海外基金

Bioreactors to Replace Animal Testing in Bone Research
生物反应器取代骨骼研究中的动物测试
  • 批准号:
    NC/Y500562/1
  • 财政年份:
    2024
  • 资助金额:
    $ 80.07万
  • 项目类别:
    Training Grant
Animal testing of RNA aptamers as ALS drug candidate
RNA适体作为ALS候选药物的动物试验
  • 批准号:
    10453877
  • 财政年份:
    2022
  • 资助金额:
    $ 80.07万
  • 项目类别:
Implementation and Evaluation of Two SARS-CoV-2 Assays for Companion Animal Testing to Expand Vet-LIRN COVID-19 Capacity
用于伴侣动物测试的两种 SARS-CoV-2 检测的实施和评估,以扩大 Vet-LIRN COVID-19 能力
  • 批准号:
    10665685
  • 财政年份:
    2022
  • 资助金额:
    $ 80.07万
  • 项目类别:
Implementation and Evaluation of Two SARS-CoV-2 Assays for Companion Animal Testing to Expand Vet-LIRN COVID-19 Capacity
用于伴侣动物测试的两种 SARS-CoV-2 检测的实施和评估,以扩大 Vet-LIRN COVID-19 能力
  • 批准号:
    10609646
  • 财政年份:
    2022
  • 资助金额:
    $ 80.07万
  • 项目类别:
COVID-19 Animal Testing Capacity
COVID-19 动物测试能力
  • 批准号:
    10609727
  • 财政年份:
    2022
  • 资助金额:
    $ 80.07万
  • 项目类别:
Animal testing of RNA aptamers as ALS drug candidate
RNA适体作为ALS候选药物的动物试验
  • 批准号:
    10646463
  • 财政年份:
    2022
  • 资助金额:
    $ 80.07万
  • 项目类别:
Data mining tool to build database to reduce animal testing in drug development.
数据挖掘工具建立数据库以减少药物开发中的动物试验。
  • 批准号:
    10042916
  • 财政年份:
    2022
  • 资助金额:
    $ 80.07万
  • 项目类别:
    Grant for R&D
AgroPathogenMeter- developing a handheld platform for on-farm, rapid and, inexpensive animal testing
AgroPathogenMeter - 开发用于农场快速且廉价的动物测试的手持平台
  • 批准号:
    506300-2017
  • 财政年份:
    2019
  • 资助金额:
    $ 80.07万
  • 项目类别:
    Strategic Projects - Group
Development of a novel alternative to animal testing for the evaluation of respiratory allergic sensitizing potential of chemicals
开发一种新的动物试验替代方案,用于评估化学品的呼吸道过敏致敏潜力
  • 批准号:
    18K11658
  • 财政年份:
    2018
  • 资助金额:
    $ 80.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the feasibility of adapting a direct PCR diagnostics approach to in-field animal testing
研究将直接 PCR 诊断方法应用于现场动物测试的可行性
  • 批准号:
    104623
  • 财政年份:
    2018
  • 资助金额:
    $ 80.07万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了